Lushang Freda Pharmaceutical Co.,Ltd.

SHSE:600223 Rapport sur les actions

Capitalisation boursière : CN¥6.9b

Lushang Freda PharmaceuticalLtd Croissance future

Future contrôle des critères 4/6

Lushang Freda PharmaceuticalLtd is forecast to grow earnings and revenue by 28.8% and 15.8% per annum respectively. EPS is expected to grow by 27.5% per annum. Return on equity is forecast to be 9.5% in 3 years.

Informations clés

28.8%

Taux de croissance des bénéfices

27.5%

Taux de croissance du BPA

Real Estate croissance des bénéfices40.2%
Taux de croissance des recettes15.8%
Rendement futur des capitaux propres9.5%
Couverture par les analystes

Good

Dernière mise à jour03 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares

Jun 21
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Apr 16
Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Mar 28
Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 04
Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Feb 27
A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Prévisions de croissance des bénéfices et des revenus

SHSE:600223 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20265,751489517718
12/31/20255,07539735958
12/31/20244,3623152,4812,6258
9/30/20243,98623757208N/A
6/30/20244,031240242370N/A
3/31/20244,197233213418N/A
12/31/20234,579303263474N/A
9/30/20237,817130-12798N/A
6/30/202310,5904784350N/A
3/31/202312,7411081,2631,442N/A
12/31/202212,95145832998N/A
9/30/202214,543133,0703,273N/A
6/30/202213,1312404,1034,293N/A
3/31/202212,1403425,9706,250N/A
12/31/202112,3633626,5676,848N/A
9/30/202112,9297297,4737,700N/A
6/30/202114,1377107,7197,944N/A
3/31/202113,9156625,5435,712N/A
12/31/202013,6156394,2914,448N/A
9/30/202010,3165724,6804,841N/A
6/30/20209,81748239174N/A
3/31/202010,307364-4,831-4,759N/A
12/31/201910,289345-3,367-3,307N/A
9/30/201910,373222-5,546-5,516N/A
6/30/201910,159195-2,295-2,262N/A
3/31/20199,2611843,1843,222N/A
12/31/20188,8211622,0622,095N/A
9/30/201810,1051661,1201,207N/A
6/30/20188,694159N/A1,571N/A
3/31/20188,476129N/A360N/A
12/31/20178,287128N/A1,637N/A
9/30/20177,576102N/A3,215N/A
6/30/20177,90998N/A-1,495N/A
3/31/20177,37094N/A-1,127N/A
12/31/20167,64692N/A-2,468N/A
9/30/20167,151107N/A-4,768N/A
6/30/20165,870101N/A-1,056N/A
3/31/20166,118103N/A-1,723N/A
12/31/20155,864112N/A-1,798N/A
9/30/20155,109166N/A-991N/A
6/30/20156,365205N/A-1,002N/A
3/31/20155,908207N/A-1,042N/A
12/31/20145,682206N/A-2,363N/A
9/30/20146,387287N/A-2,457N/A
6/30/20145,790273N/A-2,511N/A
3/31/20145,477272N/A-2,356N/A
12/31/20135,293263N/A-1,088N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 600223's forecast earnings growth (28.8% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 600223's earnings (28.8% per year) are forecast to grow faster than the CN market (25.8% per year).

Croissance élevée des bénéfices: 600223's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: 600223's revenue (15.8% per year) is forecast to grow faster than the CN market (14% per year).

Croissance élevée des revenus: 600223's revenue (15.8% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 600223's Return on Equity is forecast to be low in 3 years time (9.5%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y